Aubrey de Grey: "Everything You Think About Aging Is Wrong"

Aubrey de Grey is a figure who does not remain invisible in the longevity field. In recent years, he founded the LEV Foundation (Longevity Escape Velocity Foundation), and he continues to be a voice that challenges assumptions. In a new interview from Longevity.Technology in 2026, de Grey presents a sharp perspective that frustrates researchers and excites his followers: according to him, aging is not a decree, but a disease that can begin to be treated today.

Who is de Grey?

De Grey, a British bio-gerontologist with a background in computer science who completed his PhD at Cambridge, built his career on one concept: aging is the accumulation of cellular damage, and damage can be repaired. He argued this in 2002, published his seminal book "Ending Aging" in 2007, and for about 20 years was one of the most prominent and controversial voices in the field. In 2021, he left the SENS Research Foundation and founded the LEV Foundation.

The SENS Approach: 7 Categories of Damage

De Grey developed a framework called SENS (Strategies for Engineered Negligible Senescence). It divides aging into 7 categories of damage that can be treated:

1. Cell loss: For example, dying neurons. Solution: Stem cells
2. Zombie cells (senescent): Solution: Senolytics
3. Protein cross-links (extracellular cross-links): Stiffen skin and arteries. Solution: Drugs that break them down
4. Extracellular aggregates: Like amyloid in Alzheimer's. Solution: Antibodies
5. Intracellular aggregates: Like lipofuscin in the eyes. Solution: Genes from bacteria that can break them down
6. Mitochondrial mutations: Solution: "Repair" genes that replicate mitochondrial genes
7. Nuclear mutations (cancer): Solution: WILT (Whole-body Interdiction of Lengthening of Telomeres)

Of these categories, only about two are currently in human clinical trials: senolytics for senescent cells, and antibodies against extracellular aggregates (like amyloid). The remaining categories are still in preclinical research stages.

The Key Insight: Longevity Escape Velocity

De Grey coined an important concept: "Longevity Escape Velocity". The idea, according to his explanations, is that if science adds more than one year to life expectancy for every year that passes, meaning life expectancy increases faster than the rate of aging, then each new treatment will buy a person enough time to reach the next treatment, and so on. He claims that at such a point, longevity could potentially become unlimited.

The calculation: For a 40-year-old today, according to de Grey, there is a significant chance of reaching LEV. He claims a probability of about 50% that a 40-year-old will not die from aging.

His Major Criticism: We Are Not Hurrying

De Grey is frustrated with the current pace of aging research. He argues that if society treated aging with an urgent effort on a scale similar to the fight against COVID-19, progress toward LEV could be significantly accelerated. He calls for a concentrated national effort against aging.

Topics Raised in the 2026 Interview

In his new interview on Longevity.Technology, de Grey discusses several updated topics:

Intrinsic Capacity

A WHO framework that measures physical, cognitive, psychological, and sensory function in the elderly. De Grey supports the approach because, he says, it allows early identification of decline and enables intervention. He describes it, according to his explanations, as a comprehensive systemic measure of body function, similar to how a blood pressure test provides a general picture of the system's state.

GLP-1 Drugs as Prevention

De Grey sees significant potential in Ozempic and similar drugs. According to him, not because of the weight loss itself, but because chronic cellular inflammation, which these drugs may reduce, is one of the main obstacles in aging. He estimates that GLP-1 drugs may in the future become part of the toolkit of aging medicine.

Longevity Clinics

De Grey supports the idea of "longevity clinics" that offer tests and treatments for longevity. But he emphasizes, according to his explanations, that many existing clinics combine a heavy marketing component alongside the science, so the public should be cautious and scrutinize carefully.

ARPA-H and Funding Limitations

He is critical of ARPA-H (a new US research arm to accelerate medical innovations): he claims it was created to solve focused goals but does not think broadly enough, and longevity research suffers from funding far below what is needed to truly advance it.

His Practical Recommendations

Why you must not wait, according to de Grey:

1. Don't wait for a miracle drug. Use what's available: senolytics in clinical research, GLP-1 in appropriate cases, metformin off-label if your doctor agrees
2. Calorie-restricted diet + solid supplements: Vitamin D, Omega-3, NAD+
3. Regular intense physical activity: A combination of cardio and strength
4. Sleep is the cheapest and has the greatest impact
5. Routine biomarker monitoring: At least once a year
6. If you have the means and leisure: Consider participating in clinical trials. It helps research and also helps you

Criticism of de Grey

It is important to note that the scientific community treats de Grey with great caution. Common criticisms:

• Overly optimistic predictions that do not always materialize on his timelines
• The SENS framework is based on assumptions that have not all been proven
• The presentation style is sometimes more theory-promoting than scientific

But even critics admit: de Grey succeeded in changing the conversation. A field once considered "science fiction" is now serious research with billions of dollars in investment.

The Bottom Line

If de Grey is only half right, we are facing a dramatic change in human life. If he is completely wrong, even then the interventions he recommends are healthy. The risk is low, the potential is huge. His recommendation is simple: Don't wait for the future. Start treating aging today.